SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Twitter

Google Plus

LinkedIn

Comments (0)

There are no comments posted here yet

Leave your comments

1. Posting comment as a guest. Sign up or login to your account.

Name (Required)

E-mail

Background

Attachments (0 / 3)

Share Your Location

Also subscribe me to this thread

Cancel Submit Comment